20079640

Source:http://linkedlifedata.com/resource/pubmed/id/20079640

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0029453, umls-concept:C0029456, umls-concept:C0043210, umls-concept:C0087111, umls-concept:C0205225, umls-concept:C0257685, umls-concept:C0593802, umls-concept:C1522673
pubmed:issue	2
pubmed:dateCreated	2010-4-12
pubmed:abstractText	Postmenopausal women with osteoporosis/osteopenia are at increased risk of fracture. Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA 124477, http://linkedlifedata.com/resource/pubmed/grant/CA-35195, http://linkedlifedata.com/resource/pubmed/grant/CA-35431, http://linkedlifedata.com/resource/pubmed/grant/CA-52352, http://linkedlifedata.com/resource/pubmed/grant/K05 CA124477-02, http://linkedlifedata.com/resource/pubmed/grant/K05 CA124477-04
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-11176760, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-11870242, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-12090977, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-12117397, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-14648009, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-15014181, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-15082697, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-15319494, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-16145047, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-16822845, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-16986348, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-17159193, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-17307102, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-18083636, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-18292978, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-18829518, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-1922205, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-3540668, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-8093403, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-8558225, http://linkedlifedata.com/resource/pubmed/commentcorrection/20079640-9875874
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9213011
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Aromatase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Bone Density Conservation Agents, http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/Nitriles, http://linkedlifedata.com/resource/pubmed/chemical/Triazoles, http://linkedlifedata.com/resource/pubmed/chemical/letrozole, http://linkedlifedata.com/resource/pubmed/chemical/zoledronic acid
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1532-3080
pubmed:author	pubmed-author:AthertonPamela JPJ, pubmed-author:DakhilShaker RSR, pubmed-author:DaltonRobert JRJ, pubmed-author:HinesStephanie LSL, pubmed-author:JohnsonDavid BDB, pubmed-author:LoprinziCharles LCL, pubmed-author:MattarBassam IBI, pubmed-author:PerezEdith AEA, pubmed-author:ReddyPavan SPS, pubmed-author:SloanJeff AJA
pubmed:copyrightInfo	Copyright 2009 Elsevier Ltd. All rights reserved.
pubmed:issnType	Electronic
pubmed:volume	19
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	92-6
pubmed:dateRevised	2011-7-27
pubmed:meshHeading	pubmed-meshheading:20079640-Aromatase Inhibitors, pubmed-meshheading:20079640-Bone Density, pubmed-meshheading:20079640-Bone Density Conservation Agents, pubmed-meshheading:20079640-Bone Diseases, Metabolic, pubmed-meshheading:20079640-Breast Neoplasms, pubmed-meshheading:20079640-Chemotherapy, Adjuvant, pubmed-meshheading:20079640-Diphosphonates, pubmed-meshheading:20079640-Female, pubmed-meshheading:20079640-Humans, pubmed-meshheading:20079640-Imidazoles, pubmed-meshheading:20079640-Nitriles, pubmed-meshheading:20079640-Osteoporosis, pubmed-meshheading:20079640-Risk Factors, pubmed-meshheading:20079640-Treatment Outcome, pubmed-meshheading:20079640-Triazoles
pubmed:year	2010
pubmed:articleTitle	Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
pubmed:affiliation	Mayo Clinic Florida, Jacksonville, FL 32224, USA. hines.stephanie@mayo.edu
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, N.I.H., Extramural